

# **Product Information Sheet for NR-3237**

SUPPORTING INFECTIOUS DISEASE RESEARCH

## Human Parainfluenza Virus 4a, M-25

### Catalog No. NR-3237

This reagent is the property of the U.S. Government.

### For research use only. Not for human use.

#### Contributor:

National Institutes of Allergy and Infectious Disease, National Institutes of Health

#### Manufacturer:

Pfizer and Company, Inc., PH-43-62-842

### **Product Description:**

Reagent: Seed Virus

Virus Classification: Paramyxoviridae, Rubulavirus

Agent: Human parainfluenza virus 4a

Strain/Isolate: M-25

NIAID Class: Research Reference Reagent

Donor (Identification #): Dr. Robert Chanock (10/06/1959)

Donor Passage History (# of passages):

Rhesus monkey kidney (7)

Producer Passage History (# of passages):

Rhesus monkey kidney (7)

Note: BEI Resources was asked to distribute this virus preparation from NIAID's historical repository. Historical characterization information is shown below in the Functional Activity and Purity sections (tests performed in June, 1969). Recent characterization information is shown on the Certificate of Analysis.

### Material Provided/Storage:

Composition: Basal Medium Eagle with 0.2% SV-5 rabbit

antiserum and 10% sucrose gelatin

Volume: 1.0 mL

Storage Temperature: -60°C or colder

Note: If homogeneity is required for your intended use,

please purify prior to initiating work.

### Functional Activity (June 1969):

Infectivity:

Conditions: Rhesus Monkey kidney

TCID<sub>50</sub>: 1 6.3 X 10<sup>4</sup> per mL

### Purity (June 1969):

Serum Neutralization Breakthrough: Negative

<u>Bacterial Sterility</u>: Negative <u>Mycoplasma</u>: Negative

### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Human Parainfluenza Virus 4a, M-25, NR-3237."

### Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

#### **Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <a href="https://www.beiresources.org">www.beiresources.org</a>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

#### **Use Restrictions:**

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

#### References:

1. The Tissue Culture Infectious Dose 50% ( $TCID_{50}$ ) endpoint is the 50% infectious endpoint in tissue culture. The  $TCID_{50}$  is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the cultures inoculated, just as a Lethal Dose 50% ( $LD_{50}$ ) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the  $TCID_{50}$  provides a measure of the titer (or infectivity) of a virus preparation.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



## **Product Information Sheet for NR-3237**

SUPPORTING INFECTIOUS DISEASE RESEARCH

- Canchola, J. G., et al. "Recovery and Identification of Human Myxoviruses." <u>Bacteriol. Rev</u>. 29 (1965): 496-503. PubMed: 4285160.
- Aguilar, J. C., et al. "Detection and Identification of Human Parainfluenza Viruses 1, 2, 3, and 4 in Clinical Samples of Pediatric Patients by Multiplex Reverse Transcription-PCR." J. Clin. Microbiol. 38 (2000): 1191-1195. PubMed: 10699020.
- Cook, M. K., et al. "Antigenic Relationships Among the Newer Myxoviruses (Parainfluenza)." <u>Am. J. Hyg.</u> 69 (1959): 250–264. PubMed: 13649677.
- Johnson, K. M., et al. "Studies on a New Human Hemadsorption Virus. I. Isolation, Properties and Characterization." <u>Am. J. Hyg.</u> 71 (1960): 81–92. PubMed 14407482.
- Abinanti, F. R., et al. "Relationships of Human and Bovine Strains of Myxovirus Para-influenza 3." <u>Proc. Soc. Exp. Biol. Med.</u> 106 (1961): 466–469. PubMed 13681035.
- Abinanti, F. R., et al. "Serologic Studies on Myxovirus Para-influenza 3 in Cattle and the Prevalence of Antibodies in Bovines." <u>J. Immunol.</u> 86 (1961): 505–511. PubMed 13681036.
- Ketler, A., V. W. Hamparian, and M. R. Hilleman. "Laboratory and Field Investigations of Bovine Myxovirus Parainfluenza 3 Virus and Vaccine. I. Properties of the SF-4 (Shipping Fever) Strain of Virus." <u>J. Immunol.</u> 87 (1961): 126–133. PubMed 13752780.
- Hilleman, M. R. "The Parainfluenza Viruses of Man." <u>Ann. N. Y. Acad. Sci.</u> 101 (1962): 564–575. PubMed 13954565.
- Jensen, K. E., B. E. Peeler, and W. G. Dulworth. "Immunization Against Parainfluenza Infections. Antigenicity of Egg Adapted Types 1 and 3." <u>J. Immunol.</u> 89 (1962): 216–227. PubMed. 14451658.
- Reisinger, R. C. "Parainfluenza 3 Virus in Cattle." <u>Ann. N. Y. Acad. Sci.</u> 101 (1962): 576–582. PubMed 13981516.
- Chanock, R. M., et al. "Myxoviruses: Parainfluenza." <u>Am. Rev. Respir. Dis.</u> 88 (1963): Suppl. 152–166. PubMed 14064929.

ATCC® is a trademark of the American Type Culture Collection.



BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

NR-3237\_14AUG2012